Celldex Therapeutics Total Assets 2010-2021 | CLDX

Celldex Therapeutics total assets from 2010 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Celldex Therapeutics Annual Total Assets
(Millions of US $)
2021 $445
2020 $236
2019 $123
2018 $156
2017 $316
2016 $383
2015 $338
2014 $248
2013 $347
2012 $126
2011 $98
2010 $110
2009 $140
Celldex Therapeutics Quarterly Total Assets
(Millions of US $)
2021-12-31 $445
2021-09-30 $460
2021-06-30 $205
2021-03-31 $219
2020-12-31 $236
2020-09-30 $256
2020-06-30 $261
2020-03-31 $113
2019-12-31 $123
2019-09-30 $132
2019-06-30 $142
2019-03-31 $148
2018-12-31 $156
2018-09-30 $168
2018-06-30 $178
2018-03-31 $191
2017-12-31 $316
2017-09-30 $319
2017-06-30 $346
2017-03-31 $360
2016-12-31 $383
2016-09-30 $252
2016-06-30 $271
2016-03-31 $302
2015-12-31 $338
2015-09-30 $353
2015-06-30 $383
2015-03-31 $408
2014-12-31 $248
2014-09-30 $272
2014-06-30 $298
2014-03-31 $319
2013-12-31 $347
2013-09-30 $181
2013-06-30 $196
2013-03-31 $224
2012-12-31 $126
2012-09-30 $120
2012-06-30 $122
2012-03-31 $137
2011-12-31 $98
2011-09-30 $108
2011-06-30 $118
2011-03-31 $92
2010-12-31 $110
2010-09-30 $112
2010-06-30 $122
2010-03-31 $132
2009-12-31 $140
2009-09-30 $48
2009-06-30 $54
2009-03-31 $63
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.402B $0.005B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00